P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.
about
Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumoursNottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?P-cadherin and the journey to cancer metastasisAlterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions.Molecular insights on basal-like breast cancer.Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.The basal epithelial marker P-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype.Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.CCAAT/enhancer binding protein β (C/EBPβ) isoforms as transcriptional regulators of the pro-invasive CDH3/P-cadherin gene in human breast cancer cells.Aberrant P-cadherin expression is associated to aggressive feline mammary carcinomasDuctal carcinoma in situ of the breast: correlation between histopathological features and age of patientsBasal breast cancer: a complex and deadly molecular subtypeIntraductal proliferative lesions of the breast-terminology and biology matter: premalignant lesions or preinvasive cancer?Demystifying basal-like breast carcinomasP-cadherin expression in breast cancer: a review.Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast.Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the BreastComparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy.Biomarkers for Basal-like Breast Cancer.Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.Basal phenotype breast cancer: implications for treatment and prognosis.Breast cancer complexity: implications of intratumoral heterogeneity in clinical management.P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer.Characteristics of basal cytokeratin expression in breast cancer.A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard.P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer.EpCAM expression is an indicator of recurrence in basal-like breast cancer.CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice.Canine mammary tumors as a model for human disease.
P2860
Q21030553-927C7AC9-96D3-4CDF-9B53-CA0D68E3B2F1Q21261291-82A29F33-41E4-4891-87DC-C3DADD8E3871Q26781906-84BF7DE9-33D2-4F21-8F19-44E7AFAAF172Q33690078-5F61089A-4891-4D5A-818B-8918E15E0928Q34123314-367370C5-E641-48DD-8B32-0283DBD6837EQ34245323-38C01F00-696C-4259-A05D-9653D587866DQ34309472-6C6ABED3-85DD-4E53-A4F8-C182D7C6C73FQ34577467-B6BF6643-7119-40E1-B47B-3EEEAEA04EFEQ34584480-E208AA20-5B5A-45F4-BA1C-2BE346605C80Q34622433-28AE0D7E-BF05-4F1F-8E0F-52586FD19BC2Q34659455-6DD80BCD-6F73-49BF-BE19-13071C6A50ECQ35931900-E1B9C491-17DC-4B7D-911F-753C90827654Q35979090-C62B8D09-F307-4DDA-88C8-8B03F7D55BA5Q36172507-81A4C32D-4587-4B04-93AD-5D169B5BF849Q36458759-50944E15-7F9A-417A-8385-EF641356C2A5Q36707715-9ADD0635-CFAC-43A8-8898-12C8627D97F7Q36845026-D9573E94-80B2-438A-8810-8675CF9A17A7Q36914879-AF7C3D6E-F44E-4710-9283-7A4DABCDF115Q36955125-590916D2-87AB-4741-8A01-6167AF23629FQ37206247-508CF9B6-71D6-42B6-AB80-19C2E6D6DAF6Q37328394-AD16E796-B599-4D41-8781-1961E324C57AQ37687380-1F8169EF-17B7-4DAF-ADE9-D4B958941EFAQ37809456-61207BE2-A369-4A9C-9138-1F632AB0A585Q37853555-77F0825C-B8DD-4456-BAF4-A101C6C3D2A3Q38656112-C262EF39-021A-4354-B4C5-3F2FC4E4199CQ39385880-6DAF60EF-9A44-472B-8733-DE62CAC17A39Q42437202-D3B796B5-FEE1-4D87-907B-E19C6702EA13Q42438922-D053D340-CC17-4EEA-9FC1-4E8268AAEB54Q42477262-8E5C387C-1943-4695-B0C9-D34AA9657D1FQ42496058-A6AEF8FB-9256-4C42-BA84-E2FF7D73D155Q45852595-2FFD0354-BE4F-47EF-9415-CD1F69ACA081Q50954857-A77CE636-E7DE-48C5-A4E4-BDE1DFBF9C10Q55368630-E9904D48-C449-419F-973B-CD7CA4AB0EBB
P2860
P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
P-cadherin and cytokeratin 5: ...... ike ductal carcinomas in situ.
@en
P-cadherin and cytokeratin 5: ...... ike ductal carcinomas in situ.
@nl
type
label
P-cadherin and cytokeratin 5: ...... ike ductal carcinomas in situ.
@en
P-cadherin and cytokeratin 5: ...... ike ductal carcinomas in situ.
@nl
prefLabel
P-cadherin and cytokeratin 5: ...... ike ductal carcinomas in situ.
@en
P-cadherin and cytokeratin 5: ...... ike ductal carcinomas in situ.
@nl
P2860
P50
P1433
P1476
P-cadherin and cytokeratin 5: ...... like ductal carcinomas in situ
@en
P2093
Fernanda Milanezi
Nair Lopes
P2860
P2888
P356
10.1007/S00428-006-0334-Y
P577
2006-11-23T00:00:00Z
P6179
1022337045